Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...
WLAX La Crosse on MSN
New rehabilitation center holds groundbreaking in Eau Claire
The Clear Sky Rehabilitation Center celebrated a groundbreaking on Bullis Farm Road in Eau Claire. The new hospital will ...
Cognitive decline and anxiety in Parkinson's disease are often only recognized at a late stage, yet they can greatly impact people's lives. Research by Marit Ruitenberg focuses on new tests and ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
ORLANDO, FLORIDA / ACCESS Newswire / October 17, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and BioVie, Inc. (Nasdaq:BIVI) on the RedChip Small Stocks, Big ...
– After 14 days of treatment in healthy volunteers, ARV-102 decreased lysosomal and neuroinflammatory microglial pathway biomarkers known to be elevated in Parkinson’s disease – NEW HAVEN, Conn., Oct.
Doctors noticed an instant improvement in Parkinson’s disease patient Denise Bacon’s mobility during the procedure, known as ...
People who were diagnosed with Parkinson’s disease in their 80s had a higher likelihood of showing evidence of brain buildup of amyloid beta, a protein linked to cognitive decline in Alzheimer’s ...
A simple skin swab based on the powers of 'super smellers' could detect devastating Parkinson's disease up to seven years before symptoms appear. Parkinson's is an incurable neurological condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback